Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Bilobalide-containing medicine composition and its prepn and use

A technology of ginkgolides and compositions, applied in the field of medicine, to achieve the effects of preventing atherosclerosis, improving microcirculation, and dilating blood vessels

Inactive Publication Date: 2006-05-17
阿尔贝拉医药控股(通化)有限公司
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, at present, there is no report that the purified ginkgolide and ligustrazine phosphate are combined in a certain ratio to make a drug for clinical use.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Dissolve the raw material with 5 times the amount of water, degrease with petroleum ether, extract the aqueous solution 5 times with an equal volume of ethyl acetate, combine the ethyl acetate extracts, wash 4 times with 0.1mol / L sodium bicarbonate solution, wash The final ethyl acetate solution was washed with water to neutrality; the ethyl acetate solution was concentrated, and the concentrated solution was diluted with water to a relative density of 1.05, filtered with an ultrafiltration membrane with a molecular weight cut-off of 200 and 600, and collected The solution is concentrated, dried and pulverized to obtain the ginkgolide extract of the present invention; wherein the ginkgolide content is greater than 85%.

Embodiment 2

[0033] Weigh the above-mentioned (containing ginkgolide 4g) ginkgolide extract and ligustrazine phosphate 40g, which can be made into 100000ml liquid medicine, and finally made into 400 bottles of large-capacity injection (the specification is 250ml / bottle). Add an appropriate amount of water for injection at 85°C to the concentrated preparation tank, put 900g of sodium chloride into the concentrated preparation tank, stir fully to dissolve completely, add activated carbon according to 0.04% of the total volume of the preparation, heat at 90°C, keep it warm for 20 minutes, and cool down to 50 ℃, decarbonize and filter the medicinal liquid into the dilute preparation tank, add ligustrazine phosphate and ginkgolide extract into the dilute preparation tank, stir well to dissolve completely, add activated carbon according to 0.02% of the total volume of the preparation, and let it stand for 20 minutes , add water for injection to the dosing volume, adjust the PH to 4.8±0.2, decarbo...

Embodiment 3

[0035] Weigh the above-mentioned ginkgolide extract (containing 8g of ginkgolide) and 40g of ligustrazine phosphate to make 2000ml liquid medicine, and finally make 1000 small volume injections. Add an appropriate amount of water for injection at 48°C in the preparation tank, then add ligustrazine phosphate and ginkgolide extract, stir well to dissolve completely, add activated carbon according to 0.02% of the total volume of the preparation, let it stand for 20 minutes, and add water for injection until the preparation is complete. Adjust the pH of the liquid to 4.5, decarbonize and filter the medicinal liquid, and then filter the medicinal liquid through the terminal, and fill it into ampoules. During filling, the ampoules are filled with nitrogen one by one, and then sterilized to obtain a small-volume injection.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention belongs to the field of medicine technology, and is especially one kind of bilobalide-containing medicine composition and its preparation and use. The medicine composition contains bilobalide and ligustrazine phosphate in the amount of 1-100 times weight of bilobalide. The medicine composition has the synergistic effect of both bilobalide and ligustrazine phosphate, possesses functions of promoting blood circulation to disperse blood clots, resisting platelet aggregation, dilating blood vessel and improving microcirculation, and is applied in preparing medicine for treating ischemic cardiac and cerebral vascular diseases.

Description

technical field [0001] The invention belongs to the field of medicine, in particular to a pharmaceutical composition containing ginkgolide and its preparation method and application, more specifically, to a pharmaceutical composition composed of ligustrazine phosphate and ginkgolide, which is prepared The method and its application in the preparation of drugs for treating ischemic cardiovascular and cerebrovascular diseases. Background technique [0002] Ginkgolide is a main active ingredient in Ginkgo biloba, which can eliminate platelet aggregation, inhibit thrombus formation, prevent atherosclerosis, and have a good protective effect on myocardial and cerebral ischemia, etc., including ginkgolide A, B, C, M, J and bilobalide. [0003] Ligustrazine phosphate is 2,3,5,6-tetramethylpyrazine phosphate monohydrate (C 8 h 12 N 2 ·H 3 PO 4 ·H 2 O), is white or off-white crystalline powder, has the effect of anti-platelet aggregation, and depolymerizes the aggregated plate...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4965A61K9/08A61K9/14A61K9/19A61K9/20A61K9/48A61K31/365A61P1/16A61P3/10
Inventor 张玉梅
Owner 阿尔贝拉医药控股(通化)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com